133 related articles for article (PubMed ID: 34547879)
21. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
22. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
23. JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
Barosi G; Klersy C; Villani L; Bonetti E; Catarsi P; Poletto V; Campanelli R; Impera S; Latagliata R; Viarengo G; Carolei A; Massa M; Musso M; Crescimanno A; Gale RP; Rosti V
Leukemia; 2016 Aug; 30(8):1772-5. PubMed ID: 26975727
[No Abstract] [Full Text] [Related]
24. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
[TBL] [Abstract][Full Text] [Related]
25. Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.
Gerlach MM; Lundberg P; Halter J; Arranto C; Wenzel F; Dirnhofer S; Tzankov A
Leuk Lymphoma; 2018 Aug; 59(8):1994-1997. PubMed ID: 29199511
[No Abstract] [Full Text] [Related]
26. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
[TBL] [Abstract][Full Text] [Related]
27. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
[TBL] [Abstract][Full Text] [Related]
28. [Small molecular compounds for BCR/ABL-negative myeloproliferative neoplasms].
Nagai T
Nihon Rinsho; 2014 Jun; 72(6):1073-8. PubMed ID: 25016807
[TBL] [Abstract][Full Text] [Related]
29. JAK inhibition: the key to treating myeloproliferative neoplasm?
Tibes R; Bogenberger JM; Mesa RA
Expert Rev Hematol; 2012 Dec; 5(6):583-5. PubMed ID: 23216589
[No Abstract] [Full Text] [Related]
30. [Ruxolitinib prescription in myelofibrosis].
Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
Lierman E; Selleslag D; Smits S; Billiet J; Vandenberghe P
Blood; 2012 Aug; 120(7):1529-31. PubMed ID: 22899477
[No Abstract] [Full Text] [Related]
32. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
33. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
Naqvi K; Daver N; Pemmaraju N; Bose P; Garcia-Manero G; Cortes J; Kantarjian HM; Verstovsek S
Leuk Lymphoma; 2017 Apr; 58(4):866-871. PubMed ID: 27494751
[TBL] [Abstract][Full Text] [Related]
35. Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.
Pacilli A; Fanelli T; Mannarelli C; Rotunno G; Pancrazzi A; Vannucchi AM; Guglielmelli P
Hematol Oncol; 2018 Feb; 36(1):357-359. PubMed ID: 28474777
[No Abstract] [Full Text] [Related]
36. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
37. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
Snider JS; Znoyko I; Lindsey KG; Morse J; Baughn LB; Hoppman NL; Pitel BA; Pearce KE; Schandl CA; Wolff DJ
Cancer Genet; 2020 Aug; 246-247():44-47. PubMed ID: 32827877
[TBL] [Abstract][Full Text] [Related]
38. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review.
Sun Y; Cai Y; Chen J; Cen J; Zhu M; Pan J; Wu D; Sun A; Chen S
Front Oncol; 2021; 11():753842. PubMed ID: 34707996
[TBL] [Abstract][Full Text] [Related]
40. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
